Skip to main content
SpringerLink
Log in

Frühtherapie bei MS

  • Chapter
  • First Online:
Betaferon®

Zusammenfassung

Die Zulassung des ersten beta-Interferon-Präparates (Interferon beta-1b) bedeutete einen Meilenstein in der Therapie der schubförmigen Multiplen Sklerose (MS). Zum ersten Mal war eine positive Verlaufsbeeinflussung der Erkrankung durch eine immunmodulatorische Basistherapie möglich geworden (The IFNB Multiple Sclerosis Study Group 1993). In den Folgejahren konnten sowohl die Zulassungsstudien der übrigen β-Interferone zur Behandlung der schubförmigen MS (PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group 1998; Jacobs et al. 1996), insbesondere aber die Frühtherapiestudien bestätigen, dass ein Therapiebeginn in frühesten Stadien der Erkrankung sinnvoll und im Falles des sogenannten klinisch isolierten Syndroms (engl. clinically isolated syndrome, CIS) in der Lage ist, die Konversion hin zu einer klinisch gesicherten MS, bzw. das Auftreten eines zweiten Schubes, signifikant hinauszuzögern.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 49.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Audoin B, Davies G, Rashid W, Fisniku L, Thompson AJ, Miller DH (2007a) Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. Multiple sclerosis 13(4):483–489. doi:10.1177/1352458506070450

    PubMed  CAS  Google Scholar 

  • Audoin B, Ibarrola D, Malikova I, Soulier E, Confort-Gouny S, Duong MV, Reuter F, Viout P, Ali-Cherif A, Cozzone PJ, Pelletier J, Ranjeva JP (2007b) Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis − a two-year longitudinal MRI/MRSI study of corpus callosum. Multiple sclerosis 13(1):41–51

    Article  PubMed  CAS  Google Scholar 

  • Audoin B, Zaaraoui W, Reuter F, Rico A, Malikova I, Confort-Gouny S, Cozzone PJ, Pelletier J, Ranjeva JP (2010) Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 81(6):690–695. doi:10.1136/jnnp.2009.188748jnnp.2009.188748

    Article  PubMed  Google Scholar 

  • Barkhof F, Filippi M, Miller DH et al (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059–2069

    Article  PubMed  Google Scholar 

  • Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W (2000) Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123(6):1174–1183

    Article  PubMed  Google Scholar 

  • Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14(3):271–278

    Article  PubMed  CAS  Google Scholar 

  • Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346(3):158–164. doi:10.1056/NEJMoa011341346/3/158

    Article  PubMed  Google Scholar 

  • Brex PA, Jenkins R, Fox NC, Crum WR, O’Riordan JI, Plant GT, Miller DH (2000) Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54(8):1689–1691

    Article  PubMed  CAS  Google Scholar 

  • Broman T, Andersen O, Bergmann L (1981) Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol Scand 63(1):6–33

    Article  PubMed  CAS  Google Scholar 

  • Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L (2012) Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet neurology 11(1):33–41. doi:10.1016/S1474-4422(11)70262-9S1474-4422(11)70262-9

    Article  PubMed  CAS  Google Scholar 

  • Comi G, Filippi M, Barkhof F, Durelli L, an G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582. doi:S0140673600047255 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374(9700):1503–1511. doi:10.1016/S0140-6736(09)61259-9S0140-6736(09)61259-9

    Article  PubMed  CAS  Google Scholar 

  • Confavreux C, Aimard G, Devic M (1980) Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103(2):281–300

    Article  PubMed  CAS  Google Scholar 

  • Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126(Pt 4):770–782

    Article  PubMed  Google Scholar 

  • Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343(20):1430–1438. doi:10.1056/NEJM200011163432001

    Article  PubMed  CAS  Google Scholar 

  • Cottrell DA, Kremenchutzky M, Rice GP, Koopman WJ, Hader W, Baskerville J, Ebers GC (1999) The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122(Pt 4):625–639

    Article  PubMed  Google Scholar 

  • Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, McDonald WI, Miller DH (1995) Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 118(6):1583–1592

    Article  PubMed  Google Scholar 

  • De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, Korteweg T, Enzinger C, Fazekas F, Calabrese M, Dinacci D, Tedeschi G, Gass A, Montalban X, Rovira A, Thompson A, Comi G, Miller DH, Filippi M (2010) Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74(23):1868–1876. doi:10.1212/WNL.0b013e3181e2413674/23/1868

    Article  PubMed  Google Scholar 

  • De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Archives of neurology 58(1):65–70

    Article  PubMed  Google Scholar 

  • DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM (2006) The contribution of demyelination to axonal loss in multiple sclerosis. Brain 129(Pt 6):1507–1516. doi:10.1093/brain/awl074

    Article  PubMed  CAS  Google Scholar 

  • Di Filippo M, Anderson VM, Altmann DR, Swanton JK, Plant GT, Thompson AJ, Miller DH (2010) Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 81(2):204–208. doi:10.1136/jnnp.2009.171769jnnp.2009.171769

    Article  PubMed  Google Scholar 

  • Edan G, Kappos L, Montalban X et al (2012) Early initiation of Interferon beta-1b after a first clinicalevent suggestive of multiple sclerosis: clinical outcomes and use of disease-modifying therapy from the BENEFIT extension study. American Academy of Neurology (AAN). 64rd Annual Meeting, New Orleans, April 21–28, 2012. Neurology 78(1):PD5002

    Google Scholar 

  • Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH (2008) Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131(3):808–817. doi:10.1093/brain/awm329awm329

    Article  PubMed  CAS  Google Scholar 

  • Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898–904. doi:10.1056/NEJM200009283431301

    Article  PubMed  CAS  Google Scholar 

  • Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of neurology 39(3):285–294. doi:10.1002/ana.410390304

    Article  PubMed  CAS  Google Scholar 

  • Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, Turan F, Ozmenoglu M, Togrul E, Demirkiran M (1998) Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 51(3):765–772

    Article  PubMed  CAS  Google Scholar 

  • Kappos L, Polman C, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249

    Article  PubMed  CAS  Google Scholar 

  • Kappos L, Freedman MS, Polman CH, an G, Hartung HP, Miller DH, Montalban X, Barkhof F, Radu EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389–397. doi:10.1016/S0140-6736(07)61194-5

    Article  PubMed  CAS  Google Scholar 

  • Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Radu EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet neurology 8(11):987–997. doi:10.1016/S1474-4422(09)70237-6S1474-4422(09)70237-6 [pii]10.1212/01.wnl.0000237994.95410.ce

    Article  PubMed  CAS  Google Scholar 

  • Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, Ebers GC (1999) The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 122(10):1941–1950

    Article  PubMed  Google Scholar 

  • Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC (2006) The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129(3):584–594. doi:10.1093/brain/awh721

    Article  PubMed  CAS  Google Scholar 

  • Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125(10):2202–2212

    Article  PubMed  Google Scholar 

  • Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G (2010) Evidence for a two-stage disability progression in multiple sclerosis. Brain 133(7):1900–1913. doi:10.1093/brain/awq076

    Article  PubMed  Google Scholar 

  • Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ (1996a) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119(6):2009–2019

    Article  PubMed  Google Scholar 

  • Losseff NA, Webb SL, O’Riordan JI, Page R, Wang L, Barker GJ, Tofts PS, McDonald WI, Miller DH, Thompson AJ (1996b) Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119(3):701–708

    Article  PubMed  Google Scholar 

  • Matthews PM, De Stefano N, Narayanan S, Francis GS, Wolinsky JS, Antel JP, Arnold DL (1998) Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Seminars in neurology 18(3):327–336. doi:10.1055/s-2008-1040884

    Article  PubMed  CAS  Google Scholar 

  • McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127

    Article  PubMed  CAS  Google Scholar 

  • Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple sclerosis 14(9):1157–1174. doi:10.1177/1352458508096878

    Article  PubMed  CAS  Google Scholar 

  • Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA (2004) Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Archives of neurology 61(2):217–221. doi:10.1001/archneur.61.2.217

    Article  PubMed  Google Scholar 

  • Myhr KM, Riise T, Vedeler C, Nortvedt MW, Gronning R, Midgard R, Nyland HI (2001) Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Multiple sclerosis 7(1):59–65

    PubMed  CAS  Google Scholar 

  • Oberwahrenbrock T, Ringelstein M, Jentschke S, Deuschle K, Klumbies K, Bellmann-Strobl J, Harmel J, Ruprecht K, Schippling S, Hartung HP, Aktas O, Brandt AU, Paul F (2013) Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler. 2013 May 23. [Epub ahead of print] PubMed PMID: 23702433.

    Google Scholar 

  • O’Riordan JI, Thompson AJ, Kingsley DPE et al (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121:495–503

    Article  PubMed  Google Scholar 

  • Paolillo A, Pozzilli C, Gasperini C, Giugni E, Mainero C, Giuliani S, Tomassini V, Millefiorini E, Bastianello S (2000) Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‚black holes‘, disease duration and clinical disability. J Neurol Sci 174(2):85–91

    Article  PubMed  CAS  Google Scholar 

  • Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the „McDonald Criteria“. Ann Neurol 58:840–846

    Article  PubMed  Google Scholar 

  • Polman CH, Reingold SC, Banwell B et al (2010) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302

    Article  Google Scholar 

  • PRISMS (Prevention of Relapses and Disability by interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504

    Article  Google Scholar 

  • Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC (2010) The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133(7):1914–1929. doi:10.1093/brain/awq118awq118

    Article  PubMed  Google Scholar 

  • The Multiple Sclerosis study group IFNB (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661

    Article  Google Scholar 

  • The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45:1277–1285

    Article  Google Scholar 

  • Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31:247–269. doi:10.1146/annurev.neuro.30.051606.094313

    Article  PubMed  CAS  Google Scholar 

  • Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338(5):278–285. doi:10.1056/NEJM199801293380502

    Article  PubMed  CAS  Google Scholar 

  • Tremlett H, Yinshan Z, Devonshire V (2008) Natural history of secondary-progressive multiple sclerosis. Multiple sclerosis 14(3):314–324. doi:10.1177/1352458507084264

    Article  PubMed  Google Scholar 

  • Wattjes MP, Harzheim M, Lutterbey GG, Klotz L, Schild HH, Traber F (2007) Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR American journal of neuroradiology 28(8):1517–1522. doi:10.3174/ajnr.A0594

    Article  PubMed  CAS  Google Scholar 

  • Weinshenker BG (1998) The natural history of multiple sclerosis: update 1998. Seminars in neurology 18(3):301–307. doi:10.1055/s-2008-1040881

    Article  PubMed  CAS  Google Scholar 

  • Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112(6):1419–1428

    Article  PubMed  Google Scholar 

  • Weinshenker BG, Ebers GC (1987) The natural history of multiple sclerosis. Can J Neurol Sci 14(3):255–261

    PubMed  CAS  Google Scholar 

  • Zivadinov R, Reder AT, Filippi M, Minagar A, Stuve O, Lassmann H, Racke MK, Dwyer MG, Frohman EM, Khan O (2008) Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71(2):136–144. doi:10.1212/01.wnl.0000316810.01120.05

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie, UniversitätsSpital Zürich, Frauenklinikstraße 26, 8091, Zürich, Schweiz

    Helen Könnecke Dr. & Sven Schippling OA Dr.

Authors
  1. Helen Könnecke Dr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sven Schippling OA Dr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helen Könnecke Dr. .

Editor information

Editors and Affiliations

  1. Medizinische Universität Innsbruck Universitätsklinik für Neurologie, Innsbruck, Austria

    Thomas Berger

  2. Leitender Arzt Klinik für Neurologie, Universitätsspital Zürich, Zürich, Switzerland

    Michael Linnebank

  3. Klinik für Allgemeine Neurologie, Universitätsklinikum Münster, Münster, Germany

    Heinz Wiendl

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Wien

About this chapter

Cite this chapter

Könnecke, H., Schippling, S. (2013). Frühtherapie bei MS. In: Berger, T., Linnebank, M., Wiendl, H. (eds) Betaferon®. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1766-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1766-8_4

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1765-1

  • Online ISBN: 978-3-7091-1766-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation